<DOC>
	<DOC>NCT01164579</DOC>
	<brief_summary>Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate na√Øve. The efficacy will be evaluated by exploring the effects on joint structure assessed by magnetic resonance imaging, x-rays and by standard clinical assessment.</brief_summary>
	<brief_title>Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Adult patients with moderate to severe early rheumatoid arthritis (&lt; 2 years) who are methotrexate and biologic disease modifying antirheumatic drug naive. Pregnant or lactating patients; Patients with renal or hepatic impairment or other severe or progressing disease; Patients with contraindication to magnetic resonance imaging with gadolinium contrast.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Early Rheumatoid Arthritis</keyword>
	<keyword>Joint Structure</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Janus Kinase (JAK) Inhibitor</keyword>
	<keyword>Tasocitinib</keyword>
	<keyword>Tofacitinib</keyword>
</DOC>